Guru Sonpavde: Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy in MIBC
Guru Sonpavde, Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida, shared a post on LinkedIn about his recent paper published in Urologic Oncology: Seminars and Original Investigations:
“Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy Phase 3 clinical trials (2,220 patients) demonstrated significantly improved disease-free survival (DFS) for PD1/L1 inhibitor therapy in the
- intention-to-treat cohorts (HR 0.76, 95% CI 0.65-0.90),
- negative PD-L1 expression (HR 0.76, 95% CI 0.64-0.90),
- those who received prior NAC (HR 0.69, 95% CI 0.52-0.91),
- lower tract (HR 0.71, 95% CI 0.55-0.92) but not upper tract disease (HR 1.21, 95% CI 0.87-1.68).
Caveats of meta-analysis apply- coauthoring from AdventHealth Central Florida Cancer Institute in a study led by Raj Satkunasivam.”
Authors: Laura Oscar-Thompson, Carlos Riveros, Guru Sonpavde, Andrea Apolo, Aly-Khan Lalani, Christopher Wallis, Raj Satkunasivam.
More posts featuring Guru Sonpavde.
Dr. Guru Sonpavde is the Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida and the Chair of Bladder Cancer Research.
He is also a Professor of Medicine at the University of Central Florida. His primary focus is drug development, leading innovative clinical trials on novel immunotherapies and targeted therapies for genitourinary cancers, especially bladder cancer, along with prostate, kidney, penile, and testicular cancers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023